Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer

Journal Article · Thu Mar 15 04:00:00 EDT 2007 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2006.10.034· OSTI ID:20944755

Garces, Yolanda I ^[1]; Okuno, Scott H ^[1]; Schild, Steven E ^[2]; Mandrekar, Sumithra J ^[1]; Bot, Brian M ^[1]; Martens, John M ^[3]; Wender, Donald B ^[4]; Soori, Gamini S ^[5]; Moore, Dennis F ^[6]; Kozelsky, Timothy F ^[1]; Jett, James R ^[1]

---

1. Mayo Clinic and Mayo Foundation, Rochester, MN (United States)
2. Mayo Clinic Scottsdale, Scottsdale, AZ (United States)
3. Iowa Oncology Research Association, Des Moines, IA (United States)
4. Siouxland Hematology-Oncology Associates, Sioux City, IA (United States)
5. Missouri Valley Cancer Consortium, Omaha, NE (United States)
6. Wichita Community Clinical Oncology Program, Wichita, KS (United States)

Purpose: The primary goal was to identify the maximum tolerable dose (MTD) of thoracic radiation therapy (TRT) that can be given with chemotherapy and amifostine for patients with limited-stage small-cell lung cancer (LSCLC). Methods and Materials: Treatment began with two cycles of topotecan (1 mg/m{sup 2}) Days 1 to 5 and paclitaxel (175 mg/m{sup 2}) Day 5 (every 3 weeks) given before and after TRT. The TRT began at 6 weeks. The TRT was given in 120 cGy fractions b.i.d. and the dose escalation (from 4,800 cGy, dose level 1, to 6,600 cGy, dose level 4) followed the standard 'cohorts of 3' design. The etoposide (E) (50 mg/day) and cisplatin (C) (3 mg/m{sup 2}) were given i.v. before the morning TRT and amifostine (500 mg/day) was given before the afternoon RT. This was followed by prophylactic cranial irradiation (PCI). The dose-limiting toxicities (DLTs) were defined as Grade {>=}4 hematologic, febrile neutropenia, esophagitis, or other nonhematologic toxicity, Grade {>=}3 dyspnea, or Grade {>=}2 pneumonitis. Results: Fifteen patients were evaluable for the Phase I portion of the trial. No DLTs were seen at dose levels 1 and 2. Two patients on dose level 4 experienced DLTs: 1 patient had a Grade 4 pneumonitis, dyspnea, fatigue, hypokalemia, and anorexia, and 1 patient had a Grade 5 hypoxia attributable to TRT. One of 6 patients on dose level 3 had a DLT, Grade 3 esophagitis. The Grade {>=}3 toxicities seen in at least 10% of patients during TRT were esophagitis (53%), leukopenia (33%), dehydration (20%), neutropenia (13%), and fatigue (13%). The median survival was 14.5 months. Conclusion: The MTD of b.i.d. TRT was 6000 cGy (120 cGy b.i.d.) with EP and amifostine.

• OSTI ID: 20944755
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 67; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANOREXIA
ANOXIA
CARCINOMAS
CHEMOTHERAPY
DEHYDRATION
FATIGUE
IRRADIATION
LEUKOPENIA
LUNGS
PATIENTS
PNEUMONITIS
RADIATION DOSES
RADIOTHERAPY
TOXICITY